Pharmaceutical Manufacturing Compliance Can No Longer Be Delegated

In 2025, regulators published frameworks that explicitly define how AI can and cannot be used in critical GMP processes.

The FDA issued draft guidance on assessing the credibility of AI models used in regulated decisions. The European Commission published draft GMP Annex 22 on artificial intelligence in pharmaceutical manufacturing.

Both describe the same requirement in slightly different language:

In critical processes, AI systems must be validated, controlled, and defensible.

Black-box systems that update on external schedules cannot meet that requirement.

This creates a market split. Manufacturers that own validated, controlled AI infrastructure before enforcement tightens will have working systems, compliance evidence, and solved governance problems. Manufacturers that wait will be retrofitting compliance into systems that were never designed for it.

This is a window. It is open now. It will not stay open long.

Why This Matters

GMP under 21 CFR Parts 211 and 600 applies fully to AI used in manufacturing and quality control.

If a model makes or supports a decision about product quality, batch disposition, process control, or deviation management, that model becomes part of the quality system.

It must be qualified and validated. The manufacturer must demonstrate that it performs as intended on its products, in its processes, and under its operating conditions.

The model must also remain under change control.

When it changes, the change must move through the manufacturer’s quality system. When an investigator asks why a batch was accepted or a deviation was missed, the manufacturer must be able to provide a complete answer.

This is where vendor-hosted systems create structural compliance exposure:

• Models update on the vendor’s schedule
• Changes occur outside the manufacturer’s approval process
• Validation becomes outdated when the underlying model changes
• Audit trails and decision logic may remain outside the manufacturer’s control
• Black-box systems cannot be independently explained or continuously defended
• Centralized vendor platforms cannot provide each manufacturer with independent change control

A model you cannot control cannot remain validated.

The only way to run AI in critical GMP processes is to own it, control it, validate it, and be able to defend it to a regulator.

What You’ll Learn

Inside the report, you’ll discover:

• What the FDA and EU GMP frameworks require from AI used in critical processes
• Why AI does not create an exemption from existing GMP obligations
• Why vendor-controlled model updates break change control
• What owned, validated AI infrastructure looks like in production
• How vision inspection can be trained and validated on specific products and operating conditions
• How reasoning systems can support deviation and batch review while final judgment remains human
• How AI can support process monitoring under controlled retraining
• What change control for AI models requires
• How to establish model qualification and validation protocols
• How performance monitoring and drift detection support continued validation
• What audit trails, documentation, training, and competency evidence must contain
• A five-phase, 12-to-16-week Proof of Concept framework
• How to demonstrate a compliant AI system in one critical GMP process
• Why vision inspection is a practical starting point
• How owned infrastructure supports regulatory confidence before enforcement tightens

Download the Pharmaceutical Validated AI Infrastructure Report

Learn how pharmaceutical manufacturers can move from vendor-controlled AI systems to owned, validated, and controlled infrastructure that can withstand regulatory scrutiny.

Build the governance, validation evidence, performance monitoring, audit trails, and change-control framework required to use AI in critical GMP processes.